JP2025031720A5 - - Google Patents

Download PDF

Info

Publication number
JP2025031720A5
JP2025031720A5 JP2024204631A JP2024204631A JP2025031720A5 JP 2025031720 A5 JP2025031720 A5 JP 2025031720A5 JP 2024204631 A JP2024204631 A JP 2024204631A JP 2024204631 A JP2024204631 A JP 2024204631A JP 2025031720 A5 JP2025031720 A5 JP 2025031720A5
Authority
JP
Japan
Prior art keywords
patient
composition
hydroxyvitamin
optionally
increase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024204631A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025031720A (ja
Filing date
Publication date
Priority claimed from PCT/IB2020/000089 external-priority patent/WO2020161543A1/en
Application filed filed Critical
Publication of JP2025031720A publication Critical patent/JP2025031720A/ja
Publication of JP2025031720A5 publication Critical patent/JP2025031720A5/ja
Pending legal-status Critical Current

Links

JP2024204631A 2019-02-06 2024-11-25 カルシフェジオールを用いた副甲状腺機能亢進症の進行を制御する方法、およびそれに使用するための組成物 Pending JP2025031720A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962802148P 2019-02-06 2019-02-06
US62/802,148 2019-02-06
PCT/IB2020/000089 WO2020161543A1 (en) 2019-02-06 2020-02-06 Method of controlling progression of hyperparathyroidism with calcifediol, and compositions for use therein
JP2021569596A JP2022519789A (ja) 2019-02-06 2020-02-06 カルシフェジオールを用いた副甲状腺機能亢進症の進行を制御する方法、およびそれに使用するための組成物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021569596A Division JP2022519789A (ja) 2019-02-06 2020-02-06 カルシフェジオールを用いた副甲状腺機能亢進症の進行を制御する方法、およびそれに使用するための組成物

Publications (2)

Publication Number Publication Date
JP2025031720A JP2025031720A (ja) 2025-03-07
JP2025031720A5 true JP2025031720A5 (https=) 2025-06-24

Family

ID=69903711

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021569596A Pending JP2022519789A (ja) 2019-02-06 2020-02-06 カルシフェジオールを用いた副甲状腺機能亢進症の進行を制御する方法、およびそれに使用するための組成物
JP2024204631A Pending JP2025031720A (ja) 2019-02-06 2024-11-25 カルシフェジオールを用いた副甲状腺機能亢進症の進行を制御する方法、およびそれに使用するための組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021569596A Pending JP2022519789A (ja) 2019-02-06 2020-02-06 カルシフェジオールを用いた副甲状腺機能亢進症の進行を制御する方法、およびそれに使用するための組成物

Country Status (9)

Country Link
US (1) US20220226351A1 (https=)
EP (1) EP3920938A1 (https=)
JP (2) JP2022519789A (https=)
KR (1) KR20210126023A (https=)
CN (1) CN113573714A (https=)
AU (2) AU2020218639A1 (https=)
CA (1) CA3128153A1 (https=)
MX (1) MX2020011741A (https=)
WO (1) WO2020161543A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025094144A1 (en) 2023-11-02 2025-05-08 Eirgen Pharma Ltd. Controlling loss of kidney function

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3095447T1 (sl) * 2006-02-03 2022-02-28 Opko Renal, Llc Zdravljenje pomanjkanja vitamina D s 25-hidroksivitaminom D2 in 25-hidroksivitaminom D3
HUE037309T2 (hu) * 2006-06-21 2018-08-28 Opko Ireland Global Holdings Ltd Terápia D-vitamin telítési szer alkalmazásával és D-vitamin hormon helyettesítõ szer
DK2148684T3 (da) 2007-04-25 2013-04-22 Cytochroma Inc Fremgangsmåde til behandling af vitamin D-insufficiens og -deficiens
PT3335712T (pt) * 2007-04-25 2025-10-23 Opko Renal Llc Método de tratamento e prevenção seguro e eficaz do hiperparatiroidismo secundário na doença renal crónica
PL2148661T3 (pl) 2007-04-25 2013-07-31 Cytochroma Inc Doustne kompozycje o kontrolowanym uwalnianiu zawierające związek będący witaminą D i woskowy nośnik
CN102046812A (zh) 2008-04-02 2011-05-04 赛特克罗公司 用于维生素d缺乏症和相关障碍的方法、组合物、用途和试剂盒
AU2013203489B2 (en) * 2008-07-24 2015-02-05 Wisconsin Alumni Research Foundation Once-a-week administration of 25-hydroxy vitamin D3 to sustain elevated steady-state pharmacokinetic blood concentration
PT2552484T (pt) 2010-03-29 2020-04-03 Opko Ireland Global Holdings Ltd Métodos e composições para redução dos níveis de parafróides
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 d 방출 제형
US10220047B2 (en) * 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
MY198547A (en) * 2016-03-28 2023-09-04 Opko Ireland Global Holdings Ltd Methods of vitamin d treatment
MX2020010338A (es) * 2018-04-03 2020-11-13 Opko Ireland Global Holdings Ltd Uso de calcifediol en pacientes de cirugia bariatrica.

Similar Documents

Publication Publication Date Title
EP3542792A1 (en) Controlled release 25-hydroxyvitamin d
CN101668532B (zh) 治疗维生素d不足和缺乏、继发性甲状旁腺功能亢进症和维生素d-响应疾病的组合物及其相应的制药用途
JP2010525078A5 (https=)
JP2017002086A5 (https=)
JP2010525079A5 (https=)
JP2004531468A5 (https=)
JP2004502638A5 (https=)
JP2025031720A5 (https=)
JP2020500864A5 (https=)
JP2016179994A (ja) イネカルシトールの新しい治療的使用
Stadler et al. Combination therapy of cutaneous T cell lymphoma with interferon alpha-2a and photochemotherapy
US6100244A (en) Method for treating respiratory distress by sublingual administration of DNA
JPWO2023078333A5 (https=)
CA2469779C (en) Method for the treatment of bone disorders
JPWO2022035828A5 (https=)
JPWO2023186829A5 (https=)
JPWO2023186816A5 (https=)
JPWO2023186832A5 (https=)
JP2001523724A (ja) 運動ニューロン病および脱髄病を治療するためのシチコリン
JPH0415766B2 (https=)
JP3816545B2 (ja) 人工透析患者の皮膚そう痒症治療組成物及び副甲状腺機能亢進症治療組成物
RU2199339C2 (ru) Способ лечения рассеянного склероза
HK40014852A (en) Controlled release 25-hydroxyvitamin d
JPWO2020161543A5 (https=)
JPWO2022093724A5 (https=)